Cargando…

Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands

SIMPLE SUMMARY: The survival of advanced melanoma patients has improved significantly over the last decade due to the introduction of new systemic therapies. It is unknown whether survival outcomes of advanced melanoma patients differ between melanoma centers in the Netherlands. This research aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Breeschoten, Jesper, van den Eertwegh, Alfonsus J. M., de Wreede, Liesbeth C., Hilarius, Doranne L., van Zwet, Erik W., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S., Stevense-den Boer, Marion A. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Boers-Sonderen, Marye J., Suijkerbuijk, Karijn P. M., Wouters, Michel W. J. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533953/ https://www.ncbi.nlm.nih.gov/pubmed/34680228 http://dx.doi.org/10.3390/cancers13205077

Ejemplares similares

The unfavorable effects of COVID‐19 on Dutch advanced melanoma care
por: van Not, Olivier J., et al.
Publicado: (2021)

Real‐world outcomes of advanced melanoma patients not represented in phase III trials
por: van Zeijl, Michiel C. T., et al.
Publicado: (2020)

Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases
por: Ismail, Rawa K., et al.
Publicado: (2020)

Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2022)

Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
por: Verver, Danielle, et al.
Publicado: (2021)

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis
por: De Meza, Melissa M., et al.
Publicado: (2023)

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
por: Ismail, Rawa K., et al.
Publicado: (2022)

Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study
por: van der Kooij, Monique K., et al.
Publicado: (2021)

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors
por: van Not, Olivier J., et al.
Publicado: (2023)

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease
por: Verheijden, Rik J, et al.
Publicado: (2020)

Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy
por: Blankenstein, Stephanie A., et al.
Publicado: (2020)

Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response
por: van der Kooij, Monique K., et al.
Publicado: (2020)

Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients
por: Biewenga, Maaike, et al.
Publicado: (2021)

Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice
por: van Zeijl, Michiel C. T., et al.
Publicado: (2021)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
por: Leeneman, Brenda, et al.
Publicado: (2020)

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
por: Schouwenburg, Maartje G., et al.
Publicado: (2019)

Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry
por: Jochems, Anouk, et al.
Publicado: (2019)

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
por: Franken, M.G., et al.
Publicado: (2021)

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
por: Mulder, E. E. A. P., et al.
Publicado: (2021)

Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis
por: Ismail, Rawa Kamaran, et al.
Publicado: (2022)

Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2009)

Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study
por: Hilarius, Doranne L., et al.
Publicado: (2011)

Targeted therapies in renal cell cancer: recent developments in imaging
por: van der Veldt, Astrid A. M., et al.
Publicado: (2010)

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: van der Veldt, A A M, et al.
Publicado: (2010)

Nipple Aspirate Fluid at a Glance
por: Patuleia, Susana I. S., et al.
Publicado: (2021)

Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
por: Verheijden, Rik J., et al.
Publicado: (2023)

Frailty and checkpoint inhibitor toxicity in older patients with melanoma
por: Bruijnen, Cheryl P., et al.
Publicado: (2022)

Comparison of Different Promoter Methylation Assays in Breast Cancer
por: Suijkerbuijk, Karijn P. M., et al.
Publicado: (2010)

Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer
por: Holleman, Marscha S., et al.
Publicado: (2022)

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study
por: Tullemans, Bibian M. E., et al.
Publicado: (2022)

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2008)

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study
por: de Joode, Karlijn, et al.
Publicado: (2020)

Low Levels of BNIP3 Promoter Hypermethylation in Invasive Breast Cancer
por: van Diest, Paul J., et al.
Publicado: (2010)

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
por: Tonk, Erwin H.J., et al.
Publicado: (2019)

Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium
por: Seferina, Shanly C., et al.
Publicado: (2017)

Response to Imported Case of Marburg Hemorrhagic Fever, the Netherlands
por: Timen, Aura, et al.
Publicado: (2009)

Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer
por: Ismail, R.K., et al.
Publicado: (2021)

Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
por: Ismail, R.K., et al.
Publicado: (2022)

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
por: Vriens, B. E. P. J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c75go3673sl692gra2tt7v4m0m